Migraine. Episodic and paroxysmal disorders
Conditions
Interventions
Intervention 1: Interventional group1: Riboflavin 50mg BID for 2 months. Intervention 2: Control group: placebo(neutral drug) for 2 months. Intervention 3: Interventional groups2: Riboflavin 100mg BI
Prevention
Interventional group1: Riboflavin 50mg BID for 2 months
Control group: placebo(neutral drug) for 2 months
Interventional groups2: Riboflavin 100mg BID for 2 months
Sponsors
Kashan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to 13 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 5-13 year-old migraineous children according to ICHD II criteria who have minimally two moderate to severe migraine attacks monthly. Exclusion criteria: Epilepsy or severe neurologic disorders ; Liver, kidney, GI, metabolic or cardiovascular disorders ; Use of migraine prophylactic drugs during the last month ; Incooperation of parents or patients ; Headache attacks less than twice per month ; Tension headache ; Mild migraine headache
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of headache. Timepoint: last month of treatment. Method of measurement: interview with parents and child.;Intensity of headache. Timepoint: last month of treatment. Method of measurement: interview with parents and child.;Frequency of headache attacks. Timepoint: last month of treatment. Method of measurement: interview with parents and child. | — |
Secondary
| Measure | Time frame |
|---|---|
| Urine color change. Timepoint: during the study weekly. Method of measurement: interview with parents and children. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Babak Soltani
Kashan University of Medical Sciences
Outcome results
None listed